Voglibose

This classification denotes a glucosidase inhibitor and anti-diabetic agent with the molecular formula C10H21NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S77P977AG8, chemically known as 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol but more generally known as voglibose, which bears US NIH Compound Identifier 5677. European Medicines Agency schedules Voglibose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00085MIG. The term VOGLIBOSE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32) WHO schedules voglibose in its Anatomical Therapeutic Chemical (ATC) Classification. VOGLIBOSE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule voglibose under HS 29221980 and SITC 51461. As of Q4 2014, VOGLIBOSE remains US FDA's Preferred Term for this commodity. Voglibose bears US NLM identifiers UMLS ID C0532578 and NCI Concept Code C95221. SMILES: C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO.